[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2020000655A1 - Tratamiento mejorado de dermatitis atópica con tradipitant. - Google Patents

Tratamiento mejorado de dermatitis atópica con tradipitant.

Info

Publication number
CL2020000655A1
CL2020000655A1 CL2020000655A CL2020000655A CL2020000655A1 CL 2020000655 A1 CL2020000655 A1 CL 2020000655A1 CL 2020000655 A CL2020000655 A CL 2020000655A CL 2020000655 A CL2020000655 A CL 2020000655A CL 2020000655 A1 CL2020000655 A1 CL 2020000655A1
Authority
CL
Chile
Prior art keywords
tradipitant
atopic dermatitis
improved treatment
treatment
improved
Prior art date
Application number
CL2020000655A
Other languages
English (en)
Inventor
Changfu Xiao
Gunther Birznieks
Andrew Heitman
Sandra Smieszek
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CL2020000655A1 publication Critical patent/CL2020000655A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

LA DESCRIPCIÓN SE REFIERE A MÉTODOS MEJORADOS PARA EL TRATAMIENTO DE LA DERMATITIS ATÓPICA Y SUS SÍNTOMAS CON TRADIPITANT.
CL2020000655A 2017-09-13 2020-03-12 Tratamiento mejorado de dermatitis atópica con tradipitant. CL2020000655A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558303P 2017-09-13 2017-09-13
US201762572456P 2017-10-14 2017-10-14

Publications (1)

Publication Number Publication Date
CL2020000655A1 true CL2020000655A1 (es) 2020-10-09

Family

ID=63684468

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000655A CL2020000655A1 (es) 2017-09-13 2020-03-12 Tratamiento mejorado de dermatitis atópica con tradipitant.

Country Status (12)

Country Link
US (1) US11549147B2 (es)
EP (2) EP4487912A3 (es)
JP (1) JP7347743B2 (es)
KR (2) KR20250036264A (es)
CN (1) CN111093671A (es)
AU (1) AU2018331267B2 (es)
BR (1) BR112020004964A2 (es)
CA (1) CA3073998A1 (es)
CL (1) CL2020000655A1 (es)
IL (1) IL272949B1 (es)
MX (2) MX2020002852A (es)
WO (1) WO2019055225A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230173743A (ko) * 2015-03-04 2023-12-27 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
JP7410137B2 (ja) 2018-06-08 2024-01-09 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントを用いる処置方法
US20230226046A1 (en) * 2020-02-25 2023-07-20 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
EP4125811A1 (en) 2020-03-26 2023-02-08 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN114127988B (zh) 2020-05-07 2024-06-28 株式会社Lg新能源 高镍电极片及其制造方法
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (es) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
KR100755577B1 (ko) 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체
PT1501808E (pt) 2002-04-26 2008-09-26 Lilly Co Eli Antagonistas de receptores taquiquininas
JP2004250329A (ja) * 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ES2340772T3 (es) 2003-10-24 2010-06-09 Eli Lilly And Company Nuevas formas cristalinas (2-(1-(3,5-bis-trifluorometilbencil)-5-piridin-4-il-1h-(1,2,3)triazol-4-il)-piridin-3-il)-(2-clorofenil)-metadona.
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) * 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
US20090264388A1 (en) 2006-02-22 2009-10-22 Valorisation Recherche Hscm, Limited Partnership Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells
PL2121610T3 (pl) 2006-12-20 2014-09-30 Lilly Co Eli Nowy półprodukt oraz sposób przydatny w wytwarzaniu {2-[1-(3,5-bistrifluorometylo-benzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)-metanonu
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
AU2014302694B2 (en) * 2013-06-24 2019-10-17 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
KR20230173743A (ko) 2015-03-04 2023-12-27 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness

Also Published As

Publication number Publication date
AU2018331267B2 (en) 2024-03-07
EP4487912A3 (en) 2025-03-26
CN111093671A (zh) 2020-05-01
KR20200054232A (ko) 2020-05-19
AU2018331267A1 (en) 2020-04-16
EP4487912A2 (en) 2025-01-08
US20210062262A1 (en) 2021-03-04
BR112020004964A2 (pt) 2020-09-15
KR20250036264A (ko) 2025-03-13
IL272949A (en) 2020-04-30
CA3073998A1 (en) 2019-03-21
US11549147B2 (en) 2023-01-10
EP3681505C0 (en) 2024-12-18
MX2020002852A (es) 2020-07-22
EP3681505A1 (en) 2020-07-22
JP2020533381A (ja) 2020-11-19
JP7347743B2 (ja) 2023-09-20
IL272949B1 (en) 2025-03-01
MX2024004377A (es) 2024-04-26
WO2019055225A1 (en) 2019-03-21
RU2020112222A (ru) 2021-10-13
EP3681505B1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
MX389468B (es) Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
TWD174683S (zh) 戒指
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
MX2017011279A (es) Metodo de tratamiento con tradipitant.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
TWD173737S (zh) 肌肉鍛鍊機器
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
TWD171584S (zh) 自動出入閘門
MX395060B (es) Sistemas y métodos de control adecuados para el uso con sistemas y métodos de producción de energía.
CO2017000367A2 (es) Producción microbiana de dioles grasos
MX2018007123A (es) Control remoto para el control de aparatos mediante la desviacion de la señal de realimentacion del control nativo al control remoto y metodos para el mismo.
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX386150B (es) Tasimelteon para tratar el síndrome de smith-magenis.
CL2016000672A1 (es) Bacteria aislada del género streptomyces
MX2016016664A (es) Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r).
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX385652B (es) Composicion heterofasica.
TWD179337S (zh) 管配件
TWD180363S (zh) 水龍頭
MX376367B (es) Activacion del factor x.
AU366358S (en) Laptop case